Non‑small cell lung cancer (NSCLC) represents about 85% of lung cancer cases and is principally managed with platinum‑based chemotherapy, with cisplatin remaining a cornerstone agent. Development of chemoresistance to cisplatin is a leading challenge that limits treatment efficacy. Recent work has implicated programmed lipid peroxidation or ferroptosis as an important regulated cell death pathway influencing cancer response to therapy. The molecular links between metabolic reprogramming and ferroptosis‑mediated cisplatin resistance in NSCLC have not been fully elucidated, prompting investigation into metabolic enzymes that may modulate ferroptosis sensitivity.
The enzyme phosphoenolpyruvate carboxykinase 2 (PCK2), a mitochondrial metabolic reprogramming enzyme, was reported in the source to be significantly upregulated in the setting of cisplatin resistance. According to the abstract, PCK2 overexpression enhanced resistance to ferroptosis, which the authors associate with promotion of cisplatin chemoresistance in NSCLC models. The source indicates a causative relationship whereby elevated PCK2 activity or expression confers a cellular state less susceptible to ferroptotic cell death, thereby weakening cisplatin antitumor effects.
The study identified RGB‑286638 free base (RGB) as a compound that inhibits PCK2 expression. Mechanistically, RGB is reported to directly bind to PCK2 at the arginine residue R454, and this interaction leads to activation of ferroptosis in cisplatin‑resistant cells. The abstract states that RGB inhibits PCK2 expression by this direct binding, linking target engagement to downstream ferroptotic responses.
Per the source abstract, treatment with RGB activated ferroptosis in cisplatin‑resistant NSCLC cells and restored cisplatin sensitivity both in vitro and in vivo. These observations led the authors to propose that targeting PCK2 with RGB can reverse cisplatin resistance. The abstract provides a summary of these outcomes but does not include experimental parameters, quantitative effect sizes, cell lines or animal models used, timing, or dosing information. Such methodological and outcome details were not reported in the provided source text and would be required to evaluate reproducibility and translational potential.
The findings summarized in the source support a model in which metabolic reprogramming via PCK2 modulates ferroptosis susceptibility and thereby contributes to cisplatin resistance in NSCLC. By inhibiting PCK2, RGB‑286638 appears to sensitize resistant tumor cells to ferroptosis and to cisplatin‑mediated cytotoxicity. The authors propose that targeting PCK2 is a promising strategy to overcome platinum resistance and to improve therapeutic outcomes for NSCLC patients. This suggests potential development paths including further preclinical validation, safety and pharmacology studies of RGB, and eventual clinical investigation. The source does not present clinical trial data or patient outcomes.
The abstract communicates the central observations but omits many experimental and translational details. Specifically, the provided text does not report:
Because these details were not reported in the available source abstract, readers should consult the full publication (FASEB J 2026; DOI: 10.1096/fj.202602464R; PMCID PMC13475953) for complete methods, results, figures, and supporting data before drawing conclusions about clinical application.
The source reports that mitochondrial metabolic enzyme PCK2 is upregulated in cisplatin‑resistant NSCLC and that PCK2 overexpression promotes resistance to ferroptosis, contributing to chemoresistance. The small molecule RGB‑286638 directly binds PCK2 at R454, inhibits PCK2 expression, activates ferroptosis in resistant cells, and restores cisplatin sensitivity in experimental in vitro and in vivo systems. Targeting PCK2 is proposed as a strategy to overcome cisplatin resistance in NSCLC; however, the abstract lacks experimental detail and clinical data, which are necessary to assess translational readiness.